Know Cancer

or
forgot password

Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year After Completion of Studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705


N/A
18 Years
N/A
Not Enrolling
Both
Actinic Keratoses

Thank you

Trial Information

Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year After Completion of Studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705


This is a Phase 3 longitudinal and observational study. Subjects who previously enrolled in
studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705 and were completely cleared of their
AK lesions in the selected treatment area at the end-of-study visit will return for
follow-up visits at 6 and 12 months after the EOS visit or until a recurrence of AKs.

The NCT numbers for the above mentioned studies are:

NCT00603798 - for Studies GW01-0703 and GW01-0705

NCT00605176 for Studies GW01-0702 and GW01-0704


Inclusion Criteria:



- Are willing and able to give informed consent;

- Have successfully completed one of the following studies: GW01-0702, GW01- 0703,
GW01-0704, or GW01-0705 and have been determined to be completely clear of AK lesions
at the EOS visit in the designated treatment area from the previous study

- Are willing to participate in the study as an outpatient, make visits to the study
center for follow-up evaluation, and agree to comply with all study requirements.

Exclusion Criteria:

- None. All subjects who meet the inclusion criteria above may participate.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Number of Participants With Recurrence of AK Lesions

Outcome Description:

The primary efficacy variable in this study was the absence of AK lesions(sustained clearance rate) in the previously treated area.

Outcome Time Frame:

Up to one year

Safety Issue:

No

Principal Investigator

Sharon Levy, MD

Investigator Role:

Study Director

Investigator Affiliation:

Graceway Pharmaceuticals, LLC

Authority:

United States: Food and Drug Administration

Study ID:

GW01-0803

NCT ID:

NCT00668733

Start Date:

April 2008

Completion Date:

July 2009

Related Keywords:

  • Actinic Keratoses
  • Actinic keratoses
  • Dermatologic disease
  • Keratosis
  • Keratosis, Actinic

Name

Location